| __timestamp | BeiGene, Ltd. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6930000 | 59644696 |
| Thursday, January 1, 2015 | 7311000 | 79541000 |
| Friday, January 1, 2016 | 20097000 | 98015000 |
| Sunday, January 1, 2017 | 62602000 | 103958000 |
| Monday, January 1, 2018 | 195385000 | 103654000 |
| Tuesday, January 1, 2019 | 388249000 | 128951000 |
| Wednesday, January 1, 2020 | 600176000 | 135799000 |
| Friday, January 1, 2021 | 990123000 | 149883000 |
| Saturday, January 1, 2022 | 1277852000 | 220206000 |
| Sunday, January 1, 2023 | 1504501000 | 265542000 |
Unlocking the unknown
In the competitive world of biotechnology, operational efficiency is key. This analysis compares the Selling, General, and Administrative (SG&A) expenses of BeiGene, Ltd. and Travere Therapeutics, Inc. from 2014 to 2023. Over this period, BeiGene's SG&A expenses skyrocketed by over 21,600%, reflecting its aggressive expansion and scaling efforts. In contrast, Travere Therapeutics saw a more modest increase of around 345%, indicating a steadier growth trajectory. By 2023, BeiGene's expenses were nearly six times higher than Travere's, highlighting its rapid growth strategy. This divergence in financial strategy underscores the varied approaches companies take in the biotech sector to achieve market success. As investors and stakeholders evaluate these trends, understanding the balance between cost management and growth potential becomes crucial.
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Neurocrine Biosciences, Inc.
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Insmed Incorporated
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Catalent, Inc.
Comparing SG&A Expenses: BeiGene, Ltd. vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and CRISPR Therapeutics AG
Selling, General, and Administrative Costs: BeiGene, Ltd. vs MannKind Corporation
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Geron Corporation
Genmab A/S vs Travere Therapeutics, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Alpine Immune Sciences, Inc. or Travere Therapeutics, Inc.
Amneal Pharmaceuticals, Inc. vs Travere Therapeutics, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Amicus Therapeutics, Inc. vs Travere Therapeutics, Inc.
Selling, General, and Administrative Costs: Ligand Pharmaceuticals Incorporated vs Travere Therapeutics, Inc.